Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + EP in Extensive Stage Small Cell Lung Cancer
NCT03100955Phase 3Unknown
- Sponsor
- Qingdao University
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Rivoceranib in small cell lung cancer (SCLC) (2 arms), sponsored by Qingdao University. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03100955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100955.